225Ac-PSMA-617 induced an average duration of tumor control of 9.0 months in a cohort of patients 85, 70, 60, 22.5, and 12.5% of whom had prior therapy with abiraterone, docetaxel, enzalutamide, 223RaCl2, and cabazitaxel, respectively [75]. Here, FOLH1 is linked to neoplasm.